Can knowing you and your family may get Alzheimer’s ever be positive?
By Giulia Rhodes,
The Guardian
| 09. 21. 2015
Untitled Document
At the University of Washington’s School of Medicine there is a computer database that states with certainty – albeit heavily encrypted – whether or not Sophie Leggett will develop a form of genetically inherited early onset Alzheimer’s disease. But she has chosen not to find out what it says.
A blood test is available to adult children and siblings of those who develop Alzheimer’s at a young age and have a family history of the disease. It identifies whether they carry one of the three faulty genes known to cause familial early onset Alzheimer’s, presenilin 1 (the mutation affecting Leggett’s family), presenilin 2 and amyloid precursor protein. All result in the overproduction of amyloid, a protein that builds up into the plaques on the brain which are the hallmark of Alzheimer’s.
Now 39, Leggett saw her mother and aunt develop familial early onset Alzheimer’s in their early 40s – as had their father. All died in their 50s. There is a one-in-two chance that Leggett has inherited the gene mutation.
“I focus on the 50% chance that...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...